Inflammation and immune response in COPD: where do we stand?

Area of Science:

• Pulmonary Medicine
• Immunology
• Cell Biology

Background:

• Chronic inflammatory and immune responses are increasingly recognized as critical factors in the development and progression of Chronic Obstructive Pulmonary Disease (COPD).
• The NLRP3 inflammasome has emerged as a significant mediator of airway inflammation in COPD.
• Cigarette smoke exposure triggers innate immune cells via pattern recognition receptors (PRRs), leading to cytokine production and inflammation.

Purpose of the Study:

• To provide an updated review of the roles of inflammatory and immune responses in the pathogenesis of COPD.
• To highlight recent findings on the NLRP3 inflammasome's involvement in COPD-related airway inflammation.
• To discuss the interplay of innate and adaptive immunity, infections, and autoimmunity in COPD.

Main Methods:

• Literature review and synthesis of current research on immune and inflammatory pathways in COPD.
• Analysis of evidence implicating specific immune cells (CD8+, CD4+, B lymphocytes) and molecular pathways (NLRP3 inflammasome, TLRs, PAMPs) in COPD pathogenesis.
• Discussion of findings from studies on smokers with and without COPD, and in COPD exacerbations.

Main Results:

• Specific patterns of airway and parenchymal inflammation involving CD8+ and CD4+ T cells are observed in smokers who develop COPD.
• More severe COPD cases exhibit lymphoid follicles with B lymphocytes and T cells.
• Infections (viral and bacterial) and autoimmunity represent additional significant factors influencing COPD pathogenesis.

Conclusions:

• Inflammatory and immune responses, particularly involving the NLRP3 inflammasome, are fundamental to COPD pathogenesis.
• A complex interplay of innate and adaptive immunity, environmental triggers like cigarette smoke, infections, and autoimmunity contributes to COPD.
• Further research into these immune mechanisms is crucial for developing effective COPD therapies.